Skip to main content

Advertisement

SpringerLink
Log in

Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study

  • Brief Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Introduction

Low-molecular-weight heparin (LMWH) is the standard treatment for cancer-associated venous thromboembolism (VTE). There have been no specific studies evaluating bemiparin for VTE in people with cancer. The aim of this study is to evaluate the effects of bemiparin for long-term treatment of VTE in routine clinical practice.

Methods/patients

Prospective observational study. Consecutive patients with active cancer and VTE, under treatment with bemiparin for at least 6 months, were recruited.

Results

We included 89 patients. The 6- and 9-month cumulative VTE recurrence rates were 2.4% and 5.9%, respectively. The 6-month cumulative rate of major bleeding was 1.3%, and of clinically relevant non-major bleeding, 8%.

Conclusions

The incidence of events in this study is lower than that reported in randomized trials. Bemiparin is effective and safe for the long-term treatment of cancer-associated VTE in routine clinical practice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References:s

  1. Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arc Intern Med 2006;166:458–64.

    Article  Google Scholar 

  2. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;15:110.

  3. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5:632–634.

    Article  CAS  Google Scholar 

  4. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–52.

    Article  Google Scholar 

  5. Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2015;11:e442–e444.

    Article  Google Scholar 

  6. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT. Haim N et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013;11:56–70.

    Article  CAS  Google Scholar 

  7. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med. 2002;162:1729–35.

    Article  CAS  Google Scholar 

  8. Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J; Investigators O. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Haemost 2006;12:389–396.

    Article  CAS  Google Scholar 

  9. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–153.

    Article  CAS  Google Scholar 

  10. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, et al. Long-term-low-molecular-weight heparin versus usual care in proximal vein thrombosis patients with cancer. Am J Med. 2006;119:1062–72.

    Article  CAS  Google Scholar 

  11. Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, Investigators C. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015;314:677–86.

    Article  CAS  Google Scholar 

  12. Kakkar VV, Gebska M, Kadziola Z, Saba N, Carrasco P. Bemiparin Invesigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003;89:674–80.

    Article  Google Scholar 

  13. Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P, CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost. 2010;8:1223–29.

  14. Schulman S, Kearon C; Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of International Society on thrombosis and haemostasis. Definition of major bleeding in clinical investigations of antihemostatis medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692–694.

  15. Austin PC, Fine Jason P. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391–400.

    Article  Google Scholar 

  16. Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–88

    Article  CAS  Google Scholar 

  17. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119(1 Suppl):176S–193S

    Article  CAS  Google Scholar 

  18. Raskob GE, van ESN, Verhamme P, et al. Hokusai VTE cancer investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624

  19. Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J. Clin Oncol. 2018;36:2017–23.

    Article  CAS  Google Scholar 

  20. Streiff MB, Holmstrom B, Angelini D, Ashrani A, et al. National comprehensive cancer network clinical practice guidelines in oncology: cancer associated venous thromboembolic disease-vesion 2. 2018. J Natl Compr Cancer Netw. 2018;16(11):1289–1303.

Download references

Funding

This project was funded in partly by a restricted educational grant from Laboratorios Farmacéuticos Rovi, SA. Second International Competition for grants for biomedical research bemiparin (2013).

Author information

Authors and Affiliations

  1. Thrombosis and Haemostasis Unit, Hospital Universitari de Bellvitge, IDIBELL (Institut D’Investigació Biomèdica de Bellvitge), University of Barcelona, Av Feixa Llarga, s/n 08907, L’Hospitalet de Llobregat, Barcelona, Spain

    E. Pina, J. Peris, E. Rosselló & P. Domènech

  2. Medical Oncology Department, Institut D’Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català D’Oncologia (ICO)-Hospital Duran I Reynals, University of Barcelona, Barcelona, Spain

    M. Antonio

  3. Biostatistics Unit, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

    J. Peñafiel & C. Tebe

  4. Basic Clinical Practice Department, University of Barcelona, Barcelona, Spain

    J. Peñafiel

  5. Basic Clinical Practice Department, Rovira Virgili University, Reus, Spain

    C. Tebe

Authors
  1. E. Pina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Antonio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Peris
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Rosselló
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Domènech
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Peñafiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C. Tebe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Pina.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants

The work has been conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All patients signed the informed consent form before enrolling in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pina, E., Antonio, M., Peris, J. et al. Bemiparin as a long-term treatment for venous thrombosis in cancer patients: the ELEBAMA study. Clin Transl Oncol 22, 616–620 (2020). https://doi.org/10.1007/s12094-019-02159-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02159-y

Keywords

Search

Navigation